First use of investigational antiviral drug pocapavir (V-073) for treating neonatal enteroviral sepsis

Pediatric Infectious Disease Journal

Volumn 34, Issue 1, 2015, Pages 52-54

  Torres Torres, Sanet ^a   Myers, Angela L ^a   Klatte, J Michael ^a   Rhoden, Eric E ^b   Oberste, M Steven ^b   Collett, Marc S ^c   McCulloh, Russell J ^a  

^a Pediatric Infectious Diseases   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c ViroDefense Inc   (United States)

Author keywords

Coxsackievirus; Neonatal enterovirus infection; Pocapavir

Indexed keywords

BILIRUBIN; FLUCONAZOLE; FRESH FROZEN PLASMA; GENTAMICIN; HYPERTENSIVE AGENT; IMMUNOGLOBULIN; PIPERACILLIN PLUS TAZOBACTAM; POCAPAVIR; ANTIVIRUS AGENT;

ABDOMINAL PAIN; ADD ON THERAPY; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; ASSISTED VENTILATION; BILIRUBIN BLOOD LEVEL; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; BLOOD CULTURE; CASE REPORT; CESAREAN SECTION; CONGESTIVE CARDIOMYOPATHY; COUGHING; COXSACKIE VIRUS B3; COXSACKIE VIRUS INFECTION; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EC50; ENDOTRACHEAL INTUBATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; EXTUBATION; FEMALE; FETUS HEART RATE; FEVER; HAND FOOT AND MOUTH DISEASE; HEART FUNCTION; HUMAN; HYPERINSULINISM; HYPERTRANSAMINASEMIA; HYPOTENSION; INTERNATIONAL NORMALIZED RATIO; LOWER ABDOMINAL PAIN; MYCOSIS; MYOCARDITIS; NEWBORN; NEWBORN INTENSIVE CARE; NEWBORN SEPSIS; NONHUMAN; OLIGURIA; PERITONEAL DIALYSIS; POLYMERASE CHAIN REACTION; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RESPIRATORY FAILURE; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; URINARY TRACT INFECTION; VIRUS CULTURE; ENTEROVIRUS B; ENTEROVIRUS INFECTIONS; ISOLATION AND PURIFICATION; POLIOMYELITIS VIRUS; SEPSIS; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; ENTEROVIRUS B, HUMAN; ENTEROVIRUS INFECTIONS; FEMALE; HUMANS; INFANT, NEWBORN; POLIOVIRUS; SEPSIS; TREATMENT OUTCOME;

EID: 84926217187     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000497     Document Type: Article

References (10)

1. Hawkes MT, Vaudry W. Nonpolio enterovirus infection in the neonate and young infant. Paediatr Child Health. 2005;10:383-388.
2. Verboon-Maciolek MA, Krediet TG, van Loon AM, et al. Epidemiological survey of neonatal non-polio enterovirus infection in the Netherlands. J Med Virol. 2002;66:241-245.
3. Lin TY, Kao HT, Hsieh SH, et al. Neonatal enterovirus infections: emphasis on risk factors of severe and fatal infections. Pediatr Infect Dis J. 2003;22:889-894.
4. Miyata I, Hanaoka N, Okabe N, et al. Echovirus 3 as another enterovirus causing life-threatening neonatal fulminant hepatitis. J Clin Virol. 2014;59:132-134.
5. Oberste MS, Moore D, Anderson B, et al. In vitro antiviral activity of V-073 against polioviruses. Antimicrob Agents Chemother. 2009;53:4501-4503.
6. Buontempo PJ, Cox S, Wright-Minogue J, et al. SCH 48973: a potent, broad-spectrum, antienterovirus compound. Antimicrob Agents Chemother. 1997;41:1220-1225.
7. Nix WA, Oberste MS, Pallansch MA. Sensitive, seminested PCR amplification of VP1 sequences for direct identification of all enterovirus serotypes from original clinical specimens. J Clin Microbiol. 2006;44:2698-2704.
8. Pevear DC, Tull TM, Seipel ME, et al. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother. 1999;43:2109-2115.
9. Freund MW, Kleinveld G, Krediet TG, et al. Prognosis for neonates with enterovirus myocarditis. Arch Dis Child Fetal Neonatal Ed. 2010;95:F206-F212.
10. Yen MH, Tsao KC, Huang YC, et al. Viral load in blood is correlated with disease severity of neonatal coxsackievirus B3 infection: early diagnosis and predicting disease severity is possible in severe neonatal enterovirus infection. Clin Infect Dis. 2007;44:e78-e81.